Defying Damage: Insights into Ischemic Reperfusion Injury in Liver Transplantation

Ischemic reperfusion injury (IRI) poses a significant challenge in liver transplantation, impacting graft function and patient outcomes. Ischemia primes the liver for reperfusion-induced damage, resulting in reactive oxygen species formation, inflammatory mediator release, and leukocyte activation, contributing to oxidative stress and inflammation. This review emphasizes the cellular and molecular mechanisms underlying IRI, the contributing factors, and the need for targeted strategies to minimize IRI and enhance graft viability. A comprehensive literature review was conducted using databases such as PubMed, Cochrane, Embase, Ovid, and Google Scholar, focusing on mechanisms, influencing factors, and interventions for IRI in liver transplantation, including recent pharmacological and surgical advancements. This review examines the multifaceted contributors to ischemia–reperfusion injury (IRI) in transplantation, including donor and recipient factors. It highlights key manifestations such as metabolic acidosis, calcium overloading, mitochondrial disruption, adenosine triphosphate depletion, and inflammation, as well as the impact on fibrosis and cancer recurrence. Preventative strategies such as cold preservation, preconditioning, and advanced surgical techniques are analyzed, alongside novel therapies such as miRNA-based approaches, toll-like receptor antagonists, and extracellular vesicles. This review highlights the pathophysiology, clinical impact, and emerging interventions to improve transplant outcomes in steatotic and nonsteatotic settings. Futuristic approaches to preventing liver ischemia–reperfusion injury (IRI) focus on precision molecular therapies, advanced organ preservation techniques, and targeted immunomodulation, complemented by artificial intelligence-driven personalization. These innovations hold the potential to revolutionize liver transplantation by minimizing IRI and improving long-term graft and patient outcomes.